Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.67 |
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 2/20 | 0.59 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28264985 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL27875882 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL27289034 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL27563351 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL8864049 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL27500017 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL27913957 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL27468688 | 1.00 | NAAA (0.67) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL96191 | 0.98 | NAAA (0.63) | NAAADGKAHTR2CFAAHRAD52 | |
| SCHEMBL446637 | 0.91 | DGKA (0.59) | NAAADGKAHTR2CFAAHRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693824-A | Beta-hydroxy fatty acid ester polymer and method for preparing beta-hydroxy fatty acid ester polymer by transesterification polycondensation method | 中国科学院成都有机化学有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20180327345-A1 | PRODUCTION OF ESTERS OF 3-HYDROXYPROPIONIC ACID AND ACRYLIC ACID | BASF SE (DE) | 2018-11-15 | — | — | US | disclosed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| EP-0985671-B1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| CN-1092211-C | Method for preparing plastic lens containing high-refractivity resin | MITSUI CHEMICALS INC (JP) | 2002-10-09 | — | — | CN | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| CN-1069331-C | Process for producing finished product of plastic lens | MITSUI CHEMICALS INC (JP) | 2001-08-08 | — | — | CN | disclosed |
| US-6197768-B1 | THERAPY, PREVENTION ISCHEMIC HEART DISEASE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0985671-A1 | PYRIDOCARBAZOLE DERIVATIVES HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-15 | — | — | EP | disclosed |
| US-6018046-A | SELECTIVE ACTION IN INHIBITING CYCLIC GMP-PHOSPHODIESTERASE (CGMP-PDE); PHARMACEUTICALS FOR TREATING DISEASES AGAINST WHICH THE INHIBITORY ACTION IS EFFECTIVE, SUCH AS PULMONARY HYPERTENSION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| CN-1036463-C | Aprocess for preparing a resin having a large refractive index | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-11-19 | — | — | CN | disclosed |
| CN-1149066-A | Process for producing finished product of plastic lens | MITSUI TOATSU CHEMICALS (JP) | 1997-05-07 | — | — | CN | disclosed |
| CN-1098723-A | Preparation has the method for high refractive index resins | MITSUI TOATSU CHEMICALS (JP) | 1995-02-15 | — | — | CN | disclosed |
| CN-1039429-A | Resin having high refractive index, lens comprising the resin, and method for producing the lens | MITSUI TOATSU CHEMICALS (JP) | 1990-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | NAAA 4355/4885DGKA 4877/4885HTR2C 304/4885 |
| US-20180327345-A1 | PRODUCTION OF ESTERS OF 3-HYDROXYPROPIONIC ACID AND ACRYLIC ACID | MLX, ADH1A, AGXT | NAAA 161/4885DGKA 4452/4885HTR2C 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.